These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1155 related items for PubMed ID: 8752611

  • 1. Pituitary function is altered during the same cycle in women with polycystic ovary syndrome treated with continuous or cyclic oral contraceptives or a gonadotropin-releasing hormone agonist.
    Ruchhoft EA, Elkind-Hirsch KE, Malinak R.
    Fertil Steril; 1996 Jul; 66(1):54-60. PubMed ID: 8752611
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Pituitary and ovarian function in women receiving hormonal contraception.
    Cohen BL, Katz M.
    Contraception; 1979 Nov; 20(5):475-87. PubMed ID: 393456
    [Abstract] [Full Text] [Related]

  • 4. Effects of pretreatment with an oral contraceptive on the time required to achieve pituitary suppression with gonadotropin-releasing hormone analogues and on subsequent implantation and pregnancy rates.
    Biljan MM, Mahutte NG, Dean N, Hemmings R, Bissonnette F, Tan SL.
    Fertil Steril; 1998 Dec; 70(6):1063-9. PubMed ID: 9848296
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Comparison of the effects of ovarian cauterization and gonadotropin-releasing hormone agonist and oral contraceptive therapy combination on endocrine changes in women with polycystic ovary disease.
    Taskin O, Yalcinoglu AI, Kafkasli A, Burak F, Ozekici U.
    Fertil Steril; 1996 Jun; 65(6):1115-8. PubMed ID: 8641482
    [Abstract] [Full Text] [Related]

  • 7. Influence of oral contraceptives on integrated secretion of gonadotropins.
    Dericks-Tan JS, Gudacker V, Taubert HD.
    Contraception; 1992 Oct; 46(4):369-77. PubMed ID: 1486775
    [Abstract] [Full Text] [Related]

  • 8. Dual suppression with oral contraceptives and gonadotrophin releasing-hormone agonists improves in-vitro fertilization outcome in high responder patients.
    Damario MA, Barmat L, Liu HC, Davis OK, Rosenwaks Z.
    Hum Reprod; 1997 Nov; 12(11):2359-65. PubMed ID: 9436663
    [Abstract] [Full Text] [Related]

  • 9. Gonadotropin-releasing hormone analog plus an oral contraceptive containing desogestrel in women with severe hirsutism: effects on hair, bone, and hormone profile after 1-year use.
    Castelo-Branco C, Martínez de Osaba MJ, Pons F, Fortuny A.
    Metabolism; 1997 Apr; 46(4):437-40. PubMed ID: 9109850
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Oral contraceptive pills, gonadotropin-releasing hormone agonists, or use in combination for treatment of hirsutism: a clinical research center study.
    Carr BR, Breslau NA, Givens C, Byrd W, Barnett-Hamm C, Marshburn PB.
    J Clin Endocrinol Metab; 1995 Apr; 80(4):1169-78. PubMed ID: 7714086
    [Abstract] [Full Text] [Related]

  • 12. Pulsatile luteinizing hormone patterns in long term oral contraceptive users.
    Hemrika DJ, Slaats EH, Kennedy JC, de Vries Robles-Korsen TJ, Schoemaker J.
    J Clin Endocrinol Metab; 1993 Aug; 77(2):420-6. PubMed ID: 8345046
    [Abstract] [Full Text] [Related]

  • 13. A gonadotropin-releasing hormone agonist versus a low-dose oral contraceptive for pelvic pain associated with endometriosis.
    Vercellini P, Trespidi L, Colombo A, Vendola N, Marchini M, Crosignani PG.
    Fertil Steril; 1993 Jul; 60(1):75-9. PubMed ID: 8513962
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Factors affecting pituitary gonadotropin function in users of oral contraceptive steroids.
    Scott JA, Brenner PF, Kletzky OA, Mishell DR.
    Am J Obstet Gynecol; 1978 Apr 01; 130(7):817-21. PubMed ID: 345817
    [Abstract] [Full Text] [Related]

  • 16. A long-term treatment with gonadotropin-releasing hormone agonist plus a low-dose oral contraceptive improves the recovery of the ovulatory function in patients with polycystic ovary syndrome.
    Genazzani AD, Petraglia F, Battaglia C, Gamba O, Volpe A, Genazzani AR.
    Fertil Steril; 1997 Mar 01; 67(3):463-8. PubMed ID: 9091331
    [Abstract] [Full Text] [Related]

  • 17. Ovarian 17-hydroxyprogesterone hyperresponsiveness to gonadotropin-releasing hormone (GnRH) agonist challenge in women with polycystic ovary syndrome is not mediated by luteinizing hormone hypersecretion: evidence from GnRH agonist and human chorionic gonadotropin stimulation testing.
    Ibañez L, Hall JE, Potau N, Carrascosa A, Prat N, Taylor AE.
    J Clin Endocrinol Metab; 1996 Nov 01; 81(11):4103-7. PubMed ID: 8923867
    [Abstract] [Full Text] [Related]

  • 18. Comparison of the effects of contraceptive steroid formulations containing two doses of estrogen on pituitary function.
    Scott JZ, Kletzky OA, Brenner PF, Mishell DR.
    Fertil Steril; 1978 Aug 01; 30(2):141-5. PubMed ID: 98356
    [Abstract] [Full Text] [Related]

  • 19. The mechanism of action of a new low-dosed combined oral contraceptive.
    Dericks-Tan JS, Schneider K, Taubert HD.
    Arch Gynecol; 1980 Aug 01; 229(2):107-14. PubMed ID: 6768343
    [Abstract] [Full Text] [Related]

  • 20. Effect of a combination of ethinylestradiol and desogestrel in adolescents with oligomenorrhea and ovarian hyperandrogenism.
    Nappi C, Farace MJ, Leone F, Minutolo M, Tommaselli AP, Montemagno U.
    Eur J Obstet Gynecol Reprod Biol; 1987 Jul 01; 25(3):209-19. PubMed ID: 2956138
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 58.